7 / 9
Notes:
conference
series LLC Ltd
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
Page 22
Geert C Mudde, Clin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-027
Next generation immuno-therapy: tumour specific control of immune
checkpoints
U
sing the S-TIR™ technology platform for human specific therapeutic vaccines
OncoQR ML has developed two prototype vaccines for treatment of pancreatic cancer
(TYG100) and breast cancer (OQR200). Vaccines derived from this platform consist of two
modules, the disease specific module, “immunogen” and the generic module, “warhead”,
which directs the vaccines to CD32 on antigen presenting cells, especially pDCs and B
cells. The immunogen in oncology is a tumour associated auto-antigen, against which
under normal conditions no clinically relevant immune responses can be induced. We will
present conclusive proof that it is finally possible to overcome all the tricks of cancer cells to
prevent therapeutic immune responses. No more need for bulk infusion of very expensive
and artificial monoclonal antibodies, which either try to mimic tumour specific B cell
responses (e.g. Herceptin and Perjeta) or try to activate cytotoxic T cells that by chance may
also kill tumours (e.g. Opdivo, Yervoy, Keytruda). S-TIR™ vaccines fully activate both arms
of the patient’s own immune system resulting in tumour specific polyclonal IgG responses
simultaneously with the generation and activation of tumour specific cytotoxic T cells. The
responses are reversible and boostable, thus allowing fine-tuning of the clinical responses
on a patient to patient basis. S-TIR™ vaccines in contrast to the current checkpoint inhibitors
do not induce autoimmune disease and are tumour specific.
Biography
Geert C Mudde has received his PhD in Immunology from the University of Utrecht in 1985 and started his
international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In
1992, he joined the Pharmaceutical/Biotech Industry, where he held several Senior Management positions at the
Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium
Pharmaceuticals, Martinsried, Germany, and at Igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter
BioScience in Vienna as Interim Manager, he has Co-founded the biotech company F-star Biotechnology, where he
served as “Chief Scientific Officer” from 2007 to 2009. In 2009, together with Christof Langer, he started to develop
the S-TIR™ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget
therapeutics GmbH in 2010. Since then he serves as CSO and Managing Director for S-TARget therapeutics as
well as for the S-TIR™ technology spin-off companies OncoQRMLGmbH and TYGOncology Ltd., which were both
founded in 2013.
geert.mudde@oncoqr.comGeert C Mudde
OncoQR ML GmbH, Austria